Market Report, "Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD)", published

Chronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity and the fifth-leading cause of death in the world. COPD is linked to cumulative exposure to risk factors, primarily tobacco smoke, but also environmental pollutants. The COPD marketed products landscape consists of pharmacological therapies aimed at managing the symptoms associated with COPD, although none of the available therapies have been shown to modify long-term disease progression.

The current COPD pipeline consists of 212 active products in development. Initial analysis revealed a small presence of first-in-class products, constituting 16.5% of the pipeline. In comparison to other indications, this is relatively low; however, there are some promising trends within COPD product development. The Preclinical Phase of development is the most active in terms of first-in-class products. This diminishes throughout clinical development, with only two such products being present in Phase III. However, if either of these products is approved, they would represent the first, first-in-class products to be approved for COPD since roflumilast, which was approved in 2011 by the FDA and in 2010 in the EU. Roflumilast was the first novel therapy for COPD in almost 20 years, which demonstrates the infrequency at which first-in-class products enter the COPD market. So to have two first-in-class products in Phase III and six in Phase II is a promising sign.

Full Report Details at
- http://www.fastmr.com/prod/1117238_frontier_pharma_chronic.aspx?afid=301

Report Scope

The COPD market has benefited from notable additions in recent years.

* Which classes of drug dominate the market?
* What additional benefits have newly approved therapies brought to market?
* How do the leading marketed therapies compare clinically?

The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD and novel, first-in-class therapies.

* Which molecular targets appear most frequently in the pipeline?
* To what degree is the pipeline penetrated by first-in-class innovation?
* Which target families consist of the most first-in-class products?

First-in-class products differ substantially in their clinical potential, based on their alignment to disease causing pathways.

* How well are first-in-class targets aligned to known disease causing pathways?
* Which targets are specifically found in early-stage development?
* What is the industry-wide interest in these targets?
* Which are the most promising first-in-class targets in early-stage development?

There have been 59 licensing deals and 41 co-development deals pertaining to COPD products since 2006.

* Which territories show the most deal activity?

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2015
- Frontier Pharma: Pain - Identifying and Commercializing First-in-Class Innovation
- Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation
- Frontier Pharma: Asthma - Identifying and Commercializing First-in-Class Innovation
- Frontier Pharma: Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation